04:19:43 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2023-04-13 Extra Bolagsstämma 2023
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 Ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021


ListaFirst North Denmark
IndustriVård & Omsorg
Brain+ är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa.
2023-04-25 08:25:24


Copenhagen, Denmark, April 25, 2023 - Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ informs that its Chief Financial Officer ("CFO"), Bertil S. Jessen, will be taking a one-year leave of absence for family reasons starting in May 2023.

During Bertil's absence, Hanne Leth Hillman, who has been a member of the company's board of directors since May 2021 and Chairman of the Audit Committee since September 2022, will step in to fill the CFO position. To ensure appropriate governance, Hanne will step down from the board, while holding the interim CFO position.

Hanne is currently CFO in Nanovi A/S, a private held medical device company, and she has extensive financial, capital market and investor relations experience from +20 years in the Life Science industry, including senior executive positions in publicly listed biotech companies Zealand Pharma and former Neurosearch, and from her background as biotech equity analyst.

Kim Baden-Kristensen, Chief Executive Officer "I'm pleased to welcome Hanne as interim CFO. Her profound knowledge of Brain+, both financially and business wise, from her tenure on our board will be invaluable in this role and ensure a smooth transition. Hanne's background in finance and investor relations, combined with her broad Life Science capital market and biotech industry insights, will serve her well as she takes on the responsibility for our financial planning and reporting, capital management, and investor relations efforts."

Hanne Leth Hillman, board member and incoming interim CFO "I am excited to be part of Brain+ and now for a period to take on a more operational role. Digital therapy has huge potential in dementia care, and our company stands in a unique position as one of the first movers in this field. We have introduced our first product to the market and started the journey to build a commercial business, and going forward we will carefully manage our resources to both support sales and advance our product pipeline to unlock the full long-term potential of our business. Bertil has done a tremendous job since he joined as CFO, and I am happy to pick up the financial baton until he returns, working even closer with Kim and the organization to realize new milestones and create value for our stakeholders."

Brain+ further informs that Lars Terney, Vice Chairman of the board of directors, will not stand for re-election for work related reasons, and he will be leaving the board at the company's Annual General Meeting on 26 May, 2023. Lars will remain a considerable Brain+ shareholder and there will be no changes to his pre-subscription commitment in the upcoming unit rights issue as announced in the prospectus.   

Brain+ is working to find a relevant replacement for Hanne as Chairman of the Audit Committee from May 2023 and a new board candidate as replacement for Lars.

Contact Information

The Company:

CEO, Kim Baden-Kristensen + 45 31393317
E-mail: kim@brain-plus.com
Brain+ A/S
Købmagergade 53, 3.

Certified Advisor:

Keswick Global AG
+ 43 1 740 408045 
E-mail: info@keswickglobal.com